Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported that on August 20, 2026, the Company granted inducement awards consisting of options to purchase up to 587,000 Class A Ordinary Shares (the “Options”) to thirteen newly hired employees. These awards were approved by the Compensation Committee of the Company’s Board of Directors and granted outside the Company’s 2023 Equity Incentive Plan, as amended (the “Plan”), as inducements material to the new employees’ employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The awards are subject to the terms and conditions and other provisions set forth in the Company’s Plan and the award agreements thereunder.